Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen booster immunogenicity and safety trial
IRCT20150303021315N26Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SpikoGen booster with Placebo (2 arms). Primary endpoint: Seroconversion for neutralizing antibodies. Started Dec 2021; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150303021315N26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N26.